Drugs / 67Cu-SAR-bisPSMA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04868604 | Aug 2021 → Sep 2026 overdue | castration-resistant prostate carcinoma | Clarity Pharmaceuticals Ltd | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 67Cu-SAR-bisPSMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04868604 ↗ |